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Abstract
Prion diseases, traditionally referred to as transmissible spongiform encephalopathies
(TSEs), are invariably fatal and highly infectious neurodegenerative diseases that affect
a wide variety of mammalian species, manifesting as scrapie in sheep and goats, bovine
spongiform encephalopathy (BSE or mad-cow disease) in cattle, chronic wasting dis-
ease in deer and elk, and Creutzfeldt-Jokob diseases, Gerstmann-Strussler-Scheinker
syndrome, fatal familial insomnia, and kulu in humans, etc. These neurodegenera-
tive diseases are caused by the conversion from a soluble normal cellular prion protein
(PrPC) into insoluble abnormally folded infectious prions (PrPSc), and the conversion
of PrPC to PrPSc is believed to involve conformational change from a predominantly
α-helical protein to one rich in β-sheet structure. Such a conformational change may
be amenable to study by molecular dynamics (MD) techniques. For rabbits, classical
studies show they have a low susceptibility to be infected by PrPSc, but recently it was
reported that rabbit prions can be generated through saPMCA (serial automated Pro-
tein Misfolding Cyclic Amplification) in vitro and the rabbit prion is infectious and
transmissible. In this paper, we first do a detailed survey on the research advances of
rabbit prion protein (RaPrP) and then we perform MD simulations on the NMR and
X-ray molecular structures of rabbit prion protein wild-type and mutants. The survey
shows to us that rabbits were not challenged directly in vivo with other known prion
strains and the saPMCA result did not pass the test of the known BSE strain of cattle.
Thus, we might still look rabbits as a prion resistant species. MD results indicate that
the three α-helices of the wild-type are stable under the neutral pH environment (but
under low pH environment the three α-helices have been unfolded into β-sheets), and
the three α-helices of the mutants (I214V and S173N) are unfolded into rich β-sheet
structures under the same pH environment. In addition, we found an interesting result
that the salt bridges such as ASP201–ARG155, ASP177–ARG163 contribute greatly
to the structural stability of RaPrP.
Keywords: prion diseases; rabbit prion proteins; wild-type and mutants; NMR and
X-ray structures; molecular dynamics study
1. Introduction
Bovine Spongiform Encephalopathy (BSE) (“Mad cow disease”) belongs to a con-
tagious type of Transmissible Spongiform Encephalopathies (TSEs). Scientists believe
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it is caused by Prions (the misfolding prion proteins) but they may have not yet solved
the riddle of “mad cow disease”. This is due to a prion is neither a virus, a bacteria nor
any microorganism so the disease cannot be caused by the vigilance of the organism im-
mune system and it can freely spread from one species to another species. The humans
exists the susceptibility of TSEs. For example, the human version of mad cow disease
named Creutzfeldt-Jakob Disease (CJD) and variant CJD (vCJD) just happen randomly
through infections of transplanted tissue or blood transfusions or consumption of in-
fected beef products. Cat, mink, deer, elk, moose, sheep, goat, nyala, oryx, greater
kudu, ostrich and many other animals are also susceptible to TSEs. However, rabbits,
horses and dogs seem to be unaffected by Prions (Vorberg et al. (2003); Khan et al.
(2010); Polymenidou et al. (2008); Zhang (2011a); Zhang and Liu (2011)). Scientists
do not know the reason.
The prion protein is a naturally occurring protein in vivo. Its lesions in brain are
not caused by the vigilance of the immune system. Recent studies have found that the
lesions led astray as long as by contact with other normal prion proteins. The cells
are arranged in accordance with the instruction of the gene and formed into proteins
with different shapes and functions. But, like cardboard boxes, proteins need to be
properly “folded” in order to ensure their normal work. When proteins are folded into
the wrong shape, they do not work. Under normal circumstances, the cells will su-
pervise these misfolded proteins and automatically decompose them. However, the
supervision mechanism is not with 100% insurance. Scientists found that the rate of
decomposition of prions is not quick enough and these prions accumulate and change
the cellular metabolism and eventually kill the cell. This leads to the death of neurons
in the brain. The dead neurons decompose and release more prion proteins into the
biological mechanism to cause prion diseases. The infectious diseased prion is thought
to be an abnormally folded isoform (PrPSc) of a host protein known as the prion pro-
tein (PrPC). The conversion of PrPC to PrPSc occurs post-translationally and involves
conformational change from a predominantly α-helical protein to one rich in β-sheet
amyloid fibrils. Much remains to be understood about how the normal cellular isoform
of the prion protein PrPC undergoes structural changes to become the disease asso-
ciated amyloid fibril form PrPSc. The “structural conformational” changes of PrPSc
from PrPC are just very proper to be studied by MD techniques. Classical studies
have showed that rabbits have low susceptibility to be infected by PrPSc (Vorberg et al.
(2003); Khan et al. (2010); Barlow and Rennie (1976); Fernandez-Funez et al. (2009);
Korth et al. (1997); Courageot et al. (2008); Vilette et al. (2001); Nisbet et al. (2010);
Wen et al. (2010a,b); Zhou et al. (2011); Ma et al. (2012)). However, recently there is
one exception saying that (i) rabbit prion can be produced through saPMCA (serial
automated Protein Misfolding Cyclic Amplification) in vitro (Chianini et al. (2012);
Fernndez-Borges et al. (2012)) (though not by challenging rabbits directly in vivo with
other known prion strains), and (ii) the rabbit prion generated is infectious and trans-
missible (Chianini et al. (2012)). RaPrP had already had NMR (Li et al. (2007)) and
X-ray (Khan et al. (2010)) structures in Protein Data Bank (www.rcsb.org) with PDB
entries 2FJ3, 3O79 respectively. In 2010 and 2013, the NMR and X-ray structures of
some RaPrP mutants (with PDB entries 2JOH, 2JOM, 4HLS, 4HMR, 4HMM) were
also already released into PDB bank (Wen et al. (2010b); Sweeting et al. (2013)). This
paper will study the NMR and X-ray structures of RaPrP and its I214V and S173N mu-
tants by MD techniques, in order to explain the specific mechanism about rabbit PrPC
(RaPrPC) and the conversion of PrPC →PrPSc of rabbits. Surely, the studies should
provide valuable knowledge about the rules governing the PrPC →PrPSc conversion,
which can provide some ideas for designing novel therapeutic approaches that block
2
the conversion and disease propagation.
In the MD studies, we are not only doing simulations under neutral pH environ-
ment, but also under low pH environment, because recent studies indicate that the low
pH solution system is an ideal trigger of PrPC to PrPSc conversion (Gerber et al. (2008);
Bjorndahl et al. (2011); Zhou and Huang (2013)).
Through some preliminary analyses of the MD simulation results, we have found
that salt bridge is a clear factor of the structural stability of RaPrP. This agrees with a
recent finding on salt bridges about PrPC (Zhou and Huang (2013)). The salt bridges of
the native prion protein (PrPC) have been calculated and analyzed by quantum chem-
ical calculations by Ishikawa et al. (2010) (Ishikawa and Kuwata (2010)), and the de-
tailed biophysical characteristics and NMR studies of PrPC →PrPSc conversion process
have also been reported by Bjorndahl et al. (2011) (Bjorndahl et al. (2011)). Recently,
incorporating Chou’s wenxiang diagrams (Chou et al. (1997, 2011); Zhou (2011a,b);
Zhou and Huang (2013)) further summarized their research based on the NMR, CD
(circular diagram) spectra and DLS (Dynamic light scattering) data at the low pH en-
vironment, and found that some salt bridges and the hydrophobic interactions in the
three helices of the prion proteins can affect the helical structural stability. These stud-
ies have provided the insight into the prion misfolding mechanism.
The rest of this paper is organized as follows. Firstly, we will review previous
research results on rabbit prion protein listed in the PubMed of NCBI. Secondly, we
will present the MD simulation materials and methods for NMR and X-ray structures
of RaPrPC wild-type and mutants. Thirdly, we will give analyses of MD simulation
results and discussions. Lastly, concluding remarks on RaPrP are summarized.
2. A Detailed Review on Rabbit PrP
The symptoms of TSEs were first described for sheep in 1730 and called “scrapie”
in England, “vertige” in France and “Traberkrankheit” in Germany (Verdier (2012)).
Now we know that many species such as sheep, goats, mice, humans, chimpanzees,
hamsters, cattle, elks, deers, minks, cats, chicken, pigs, turtles, etc are susceptible
to TSEs. But many laboratory experiments show that rabbits, horses and dogs seem
to be the resistant (or at least the low-susceptibility-rate) species to TSEs. However,
recently Chianini et al. (2012) reported “rabbits are not resistant to prion infection”
(Chianini et al. (2012)). Thus, at this moment it is very necessary for us to give a
detailed review some laboratory works (from Year 1976 to Year 2013) on RaPrP:
• In 1976, Barlow and Rennie (1976) made many attempts to infect rabbits with
the ME7 scrapie (where scrapie is a prion disease in sheep and goats) and other
known prion strains but all failed at last (Barlow and Rennie (1976)).
• In 1984∼1985, some antibodies to the scrapie protein were reported by Prusiner’s
research group (Bendheim et al. (1984); Barry et al. (1985). The antibodies to
the scrapie agent were produced after immunization of rabbits with either scrapie
prions or the prion protein PrP(27–30). The monospecificity of the rabbit an-
tiserum raised against PrP(27–30) was established by its reactivity after affin-
ity purification, and the rabbit antiserum to PrP(27–30) was successfully pro-
duced. In 1985, the characterization of antisera raised in rabbits, against scrapie-
associated prion diseases and the prion human CJD, was studied in (Bode et al.
(1985)).
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• In 1986, Takahashi et al. (1986) reported, rabbits immunized with the fraction
P4 containing scrapie infectivity prepared from mouse brains raised antibodies
against three major polypeptides of (Takahashi et al. (1986)). Cho (1986) re-
ported that the antibody to scrapie-associated fibril protein roduced in a rabbit
identifies a cellular antigen (Cho (1986)). Barry et al. (1986) reported that rab-
bit antisera to a synthetic peptide PrP-P1 constructed based on PrP(27–30) were
found by immunoblotting to react with PrP(27–30) and its precursor PrPSc(33–
35), as well as with a related protease-sensitive cellular homologue PrPC(33–35),
this means scrapie (PrPSc) and cellular (PrPC) prion proteins share polypeptide
epitopes (Barry et al. (1986)). An enzyme-linked immunosorbent assay showed
that rabbit antiserum to PrP(27–30) was more reactive with PrP(27–30) than with
PrP-P1; conversely, antiserum to PrP-P1 was more reactive with the peptide than
with the prion proteins (Barry et al. (1986)). Shinagawa et al. (1986) reported
“immunization of a rabbit with the (synthetic) peptide conjugated with ovalbu-
min induced specific antibodies” corresponding to the N-terminal region of the
scrapie prion protein (PrPSc) (Shinagawa et al. (1986)). “Rabbit antisera were
raised to SAFs (scrapie-associated fibrils) isolated from mice infected with the
ME7 scrapie strain and to SAFs isolated from hamsters infected with the 263K
scrapie strain” (Kascsak et al. (1986); Merz et al. (1987)). Robakis et al. (1986)
clearly pointed out that rabbit brain is resistant to scrapie infection (Robakis et al.
(1986)) in 1986.
• In 1987, there were several reports on rabbits. Bockman et al. (1987) identified
by immunoblotting human & mouse CJD prion proteins (HuPrPSc and MoPrPSc)
using rabbit antisera raised against hamster scrapie prion proteins (HaPrPSc)
(Bockman et al. (1987)). Wade et al. (1987) found a 45 kD protein in scrapie-
infected hamster brain has a signal to inoculate rabbits (Wade et al. (1987)).
Kascsak et al. (1987) reported “MAb (monoclonal antibody) 263K 3F4 (that was
derived from a mouse immunized with hamster 263K PrPSc reacted with hamster
but not mouse PrPSc) recognized normal host protein of 33 to 35 kilodaltons in
brain tissue from hamsters and humans but not from bovine, mouse, rat, sheep, or
rabbit brains” (Kascsak et al. (1987)). Wiley et al. (1987) used rabbit monospe-
cific antisera raised against synthetic peptides corresponding to the N-terminal
13 or 15 amino acids of PrP(27–30) and rabbit antisera raised against infec-
tious prions or PrP(27–30) purified from scrapie-infected hamster brains to im-
munostaine glutaraldehyde-perfused hamster brains (Wiley et al. (1987)). Hay
et al. (1987) found the evidence for a secretory form of the cellular prion protein
(PrPC) “cell-free translation studies in rabbit reticulocyte lysates supplemented
with microsomal membranes gave results: while one form of HaPrP (hamster
brain prion protein) was found as an integral membrane protein spanning the
membrane at least twice, another form of HaPrP was found to be completely
translocated to the microsomal membrane vesicle lumen” (Hay et al. (1987)).
• In 1988, Caughey et al. (1988) detected the immunoprecipitation of PrP syn-
thesis using a rabbit antibody specific for a 15 amino acid PrP peptide and con-
cluded that “either PrP is not the transmissible agent of scrapie or the PrP is
not processed appropriately in this cell system to create the infectious agent”
(Caughey et al. (1988)). Barry et al. (1988) undertook ELISA (enzyme-linked
immunosorbent assay) and immunoblotting studies with rabbit antisera raised
against three synthetic PrP peptides of PrP(27–30), PrPSc, and PrPC and con-
cluded that the three proteins are encoded by the same chromosomal gene (Barry et al.
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(1988)). Baron et al. (1998) found “polyclonal rabbit antiserum to SAF pro-
tein was reacted with brain sections from scrapie-infected mice, two familial
cases of transmissible dementia, and three cases of Alzheimer’s disease (AD)”
and “evidence of the similarity of SAF protein to PrP(27–30)” (Baron et al.
(1988)). Gabizon et al. (1988) found “polyclonal RaPrP antiserum raised against
NaDodSO4/PAGE-purified scrapie prion protein of 27–30 kDa reduced scrapie
infectivity dispersed into detergent-lipid-protein complexes” (Gabizon et al. (1988)).
Roberts et al. (1998), “using monoclonal antibodies to a synthetic peptide cor-
responding to a portion of beta-protein and rabbit antiserum to hamster scrapie
PrP(27–30), examined in situ amyloid plaques on sections from cases of neu-
rodegenerative diseases” and their “results emphasize the need for classification
of CNS (central nervous system) amyloids based on the macromolecular com-
ponents comprising these pathologic polymers” (Roberts et al. (1988)).
• In 1989, Gabizon et al. (1989) reported that “polyclonal rabbit PrP antiserum
raised against sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE)-purified PrP(27–30) reduced scrapie infectivity dispersed into DLPC (detergent-
lipid-protein complexes)” (Gabizon et al. (1989)). “Kuru plaque is a pathog-
nomonic feature in the brain of patients with CJD and in the brain of CJD-
infected mice” (Kitamoto et al. (1989)), Kitamoto et al. (1989) reported “kuru
plaques from CJD-infected mice were immunolabeled with rabbit anti-murine
prion protein (PrP) absorbed with human PrP, but not so with mouse anti-human
PrP” (Kitamoto et al. (1989)). Farquhar et al. (1989) “Two polyclonal antisera
were raised in rabbits against the scrapie-associated fibril protein (PrP) prepared
from sheep and mice” (Farquhar et al. (1989)).
• In 1990, Yost et al. (1990) reported that in the rabbit reticulocyte lysate system,
an unusual topogenic sequence in the prion protein fails to cause stop transfer
(the polypeptide chain across the membrane of the endoplasmic reticulum) of
most nascent chains (Yost et al. (1990)). Lopez et al. (1990) reported a com-
pletely translocated (secretory) topology form of the major product synthesized
in rabbit reticulocyte lysates (RRL) (Lopez et al. (1990)).
• In 1991, Di Martino et al. (1991) reported the characterization of two poly-
clonal antibodies which were raised by immunizing rabbits with two non carrier-
linked synthetic peptides whose amino acid sequences corresponded to codons
89–107 (peptide P1) and 219–233 (peptide P2) of the translated cDNA sequence
of murine PrP protein (Di Martino et al. (1991)). Ikegami et al. (1991) detected
the scrapie-associated fibrillar protein in the lymphoreticular organs of sheep by
means of a rabbit-anti-sheep PrP (the scrapie-associated fibrillar protein) poly-
clonal antibody by Western blot analysis (Ikegami et al. (1991)).
• In 1992, Hashimoto et al. (1992) did immunohistochemical study of kuru plaques
using antibodies against synthetic prion protein peptides and used two synthetic
peptides to immunize rabbits and produce antisera (anti-N and anti-M) (Hashimoto et al.
(1992)). Kirkwood et al. (1992) using rabbit antiserum raised against mouse PrP
detected an abnormal PrP (prion protein) from the brains of domestic cattle with
spongiform encephalopathy (SE) (Kirkwood et al. (1992)).
• In 1993, the Western blot analysis was performed with rabbit serum against the
sheep SAF (Onodera et al. (1993)). To determine if amyloid deposits be visu-
alized by immunocytochemical techniques, Guiroy et al. (1993) used a rabbit
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antiserum directed against scrapie amyloid PrP(27–30) to stain formalin-fixed,
formic acid-treated brain tissue sections from several animal species with nat-
ural and experimental transmissible mink encephalopathy (TME) (Guiroy et al.
(1993)). Groschup and Pfaff (1993) reported that “rabbit antisera to synthetic
peptides representing amino acid sequence 108 to 123 of PrP of cattle, sheep and
mice reacted strongly with modified PrP of the homologous host but not, or only
poorly, with PrP of heterogeneous origin” (Groschup and Pfaff (1993)). Miller
et al. (1993) did the immunohistochemical detection of prion protein in sheep
with scrapie using a primary antibody obtained from a rabbit immunized to PrPSc
extracted from brains of mice with experimentally induced scrapie (Miller et al.
(1993)).
• In 1994, Groschup et al. (1994) investigated with eight different anti-peptide sera
raised in rabbits against various synthetic peptides representing segments of the
amino acid (aa) sequence 101–122 of ovine, bovine, murine and hamster PrP, and
found that “the region close to the actual or putative proteinase K cleavage sites
of PrP seems to exhibit high structural variability among mammalian species”
(Groschup et al. (1994)). Xi et al. (1994) detected the proteinase-resistant pro-
tein (PrP) in small brain tissue samples from CJD patients using rabbit poly-
clonal antibody against hamster PrP(27–30) (Xi et al. (1994)). Schmerr et al.
(1994) used a fluorescein-labeled goat anti-rabbit immunoglobulin as an anti-
body and used rabbit antiserum for immunoblot analysis, and PrPSc was solu-
bilized and reacted with a rabbit antiserum specific for a peptide of the prion
protein (Schmerr et al. (1994)).
• In 1995∼1996, Yokoyama et al. did some works. In 1995, Yokoyama et al.
(1995) used antisera raised in rabbits against three peptides PrP 150–159, PrP
165–174, and PrP 213–226 of mouse prion and concluded that rabbit antiserum
against the MAP (multiple antigenic peptide) representing amino acid sequence
213–226 of mouse PrP is useful as a diagnostic tool for prion disease of animals
(Yokoyama et al. (1995)). In 1996, Yokoyama et al. (1996) detected species
specific epitopes of mouse and hamster prion proteins by anti-peptide antibodies,
where the antisera were produced in rabbits (Yokoyama et al. (1996)).
• In 1997, Madec et al. (1997) undertook Western blot analyses using rabbit
antiserum that recognized both normal and pathologic sheep prion proteins to
study the biochemical properties of PrPSc in natural sheep scrapie (Madec et al.
(1997)). Loftus and Rogers (1997) cloned RaPrP open reading frame (ORF) and
characterised rabbits as a species with apparent resistance to infection by prions
(Loftus and Rogers (1997)). Groschup et al. (1997) raised antisera in rabbits and
chicken against sixteen synthetic peptides which represent the complete amino
acid sequence of ovine PrP to generate antibodies to further regions of PrP, in
order to immunochemical diagnosis and pathogenetic studies on prion diseases
(Groschup et al. (1997)). In (Komar et al. (1997)),“the Ure2p yeast prion-like
protein was translated in vitro in the presence of labeled [35S]methionine in
either rabbit reticulocyte lysate (RRL) or wheat germ extract (WGE) cell-free
systems”. In 1997, Korth et al. (1997) found that RaPrP was not recognized by a
conformational antibody specific for PrPSc-like structures (Korth et al. (1997)).
• In 1999, Takahashi et al. (1999) immunized rabbits with four synthetic pep-
tides and compared the immunoreactivity of antibodies to bovine prion pro-
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teins (bovine-PrPs) from various species by immunoblotting and immunohisto-
chemistry (Takahashi et al. (1999)) and they identified two regions in bovine-PrP
which appear suitable for raising antibodies that detect various kinds of PrPs, and
one region (Ab103–121) which appears suitable for raising antibodies that detect
several species of PrP (Takahashi et al. (1999)).
• In 2000, Garssen et al. (2000) did applicability of three anti-PrP peptide sera
including staining of tonsils and brainstem of sheep with scrapie (Garssen et al.
(2000)). “The three rabbit antibodies (R521, R505, R524) were produced, and
raised to synthetic peptides corresponding to residues 94–105, 100–111, and
223–234, respectively, of the sheep prion protein” (Garssen et al. (2000)). “The
usefulness of all three anti-peptide sera in the immunohistochemical detection
of PrPSc in brain stem and tonsils of scrapie-affected sheep was demonstrated
and compared with an established rabbit anti-PrP serum” (Garssen et al. (2000)).
Zhao et al. (2000) using prokaryotic expressed GST-PrP fusion protein as anti-
gen, found that “rabbits were immunized subcutaneously” (Zhao et al. (2000)).
• In 2001, Kelker et al. (2001) showed that “combination of authentic rabbit mus-
cle GAPDH (glyceraldehyde-3-phosphate dehydrogenase) with tNOX (a cell
surface NADH oxidase of cancer cells) renders the GAPDH resistant to pro-
teinase K digestion” (Kelker et al. (2001)). Vol’pina et al. (2001) reported “rab-
bits were immunized with either free peptides or peptide-protein conjugates to
result in sera with a high level of antipeptide antibodies” to the BSE prion dis-
ease (Vol’pina et al. (2001)). Bencsik et al. (2001) identified prion protein PrP
“using either RB1 rabbit antiserum or 4F2 monoclonal antibody directed against
AA 108–123 portion of the bovine and AA 79–92 of human prion protein re-
spectively” and “showed the close vicinity of these PrP expressing cells with
noradrenergic fibers” (Bencsik et al. (2001)). In (Li et al. (2001)), “the rabbits
were immuned with bovine prion protein (BoPrPC) which was expressed in E.
coli and anti-PrPC antibody (T1) was obtained”, and Li et al. (2001) could detect
BSE and scrapie with T1 antibody (Li et al. (2001)).
• In 2002, Laude et al. (2002) reported “In one otherwise refractory rabbit ep-
ithelial cell line, a regulable expression of ovine PrP was achieved and found
to enable an efficient replication of the scrapie agent in inoculated cultures”
(Laude et al. (2002)). Takekida et al. (2002) established a competitive ELISA
to detect prion protein in food products using rabbit polyclonal antibodies that
were raised against bovine prion peptides (Takekida et al. (2002)).
• In 2003, Vorberg et al. (2003) found multiple amino acid residues (such as
GLY99, MET108, SER173, ILE214) within the RaPrP inhibit formation of its
abnormal isoform (Vorberg et al. (2003)). The authors made some substitutions
of mouse PrP amino acid sequence by rabbit PrP amino acid sequence and found
(i) at the N-terminal region (residues 1–111) the PrPSc formation is totally pre-
vented, (ii) at the central region (residues 112–177), the constructed PrP failed
to be converted to protease resistance, (iii) at the C-terminal region (residues
178–254) the formation of PrPSc is drastically decreased but is not abolished
completely (Vorberg et al. (2003)). Thus, rabbit cells are negatively affected by
the formation of PrPSc. Jackman and Schmerr (2003) synthesized fluorescent
peptides from the prion protein and produced the corresponding antibodies in
rabbits against these peptides, and at last detected abnormal prion protein in a
7
tissue sample (Jackman and Schmerr (2003)). Gilch et al. (2003) reported “treat-
ment of prion-infected mouse cells with polyclonal anti-PrP antibodies generated
in rabbit or auto-antibodies produced in mice significantly inhibited endogenous
PrPSc synthesis” and found “immune responses against different epitopes when
comparing antibodies induced in rabbits and PrP wild-type mice” (Gilch et al.
(2003)).
• In 2004, Brun et al. (2004) reported the development and further characterisation
of a novel PrP-specific monoclonal antibody 2A11, which reacts with PrPC from
a variety of species including rabbit (Brun et al. (2004)). Sachsamanoglou et al.
(2004) described “the quality of a rabbit polyclonal antiserum (Sal1) that was
raised against mature human recombinant prion protein (rHuPrP)” (Sachsamanoglou et al.
(2004)). Senator et al. (2004) investigated “the effects of cellular prion pro-
tein (PrPC) overexpression on paraquat-induced toxicity by using an established
model system, rabbit kidney epithelial A74 cells, which express a doxycycline-
inducible murine PrPC gene” (Senator et al. (2004)).
• In 2005, Golanska et al. (2005) used 2 different anti-14-3-3 antibodies: rabbit
polyclonal and mouse monoclonal antibodies to analyze the 14-3-3 protein in the
cerebrospinal fluid in CJD (Golanska et al. (2005)).
• In 2006, Dupiereux et al. (2006) investigated the effect of PrP(106-126) peptide
on an established non neuronal model, rabbit kidney epithelial A74 cells that
express a doxycycline-inducible murine PrPC gene (Dupiereux et al. (2006)).
Biswas et al. (2006) reported “a rabbit polyclonal anti-serum raised against
dimeric MuPrP (murine prion protein) cross-reacted with p46 (a 46 kDa species)
and localized the signal within the Golgi apparatus” (Biswas et al. (2006)). Gao
et al. (2006) reported recombinant neural protein PrP can bind with both recom-
binant and native apolipoprotein E (ApoE) in vitro, where the “ApoE-specific an-
tiserum was prepared by immunizing rabbits with the purified ApoE3” (Gao et al.
(2006)). Kocisko and Caughey (2006) reported “rabbit epithelial cells that pro-
duce sheep prion protein in the presence of doxycycline (Rov9) have been in-
fected with sheep scrapie” (Kocisko and Caughey (2006)). Xiao et al. (2006)
used the method “two male rabbits were immunized for 4 times with the purified
protein, and the antiserum against NSE protein was collected and evaluated by
ELISA, Western blotting and immunohistochemistry” and concluded “high ex-
pression of HuNSE (human neuron-specific enolase) is obtained in E. coli and
the prepared antiserum against HuNSE can be used potentially for diagnosis of
prion-associated diseases and other nervous degeneration diseases” (Xiao et al.
(2006)).
• In 2007, Oboznaya et al. (2007) reported “antibodies to a nonconjugated prion
protein peptide 95–123 interfere with PrPSc propagation in prion-infected cells”,
where “rabbits were immunized with free nonconjugated peptides” (Oboznaya et al.
(2007)). Handisurya et al. (2007) reported “Immunization with PrP-virus-like
particles induced high-titer antibodies to PrP in rabbit and in rat, without in-
ducing overt adverse effects. As determined by peptide-specific ELISA, rabbit
immune sera recognized the inserted murine/rat epitope and also cross-reacted
with the homologous rabbit/human epitope differing in one amino acid residue.
Rabbit anti-PrP serum contained high-affinity antibody that inhibited de novo
synthesis of PrPSc in prion-infected cells” (Handisurya et al. (2007)). Bastian et
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al. (2007) did an experiment “spiroplasma mirum, a rabbit tick isolate that had
previously been shown to experimentally induce spongiform encephalopathy in
rodents, was inoculated intracranially (IC) into ruminants” and at last concluded
“Spiroplasma spp. from TSE brains or ticks induce spongiform encephalopa-
thy in ruminants” (Bastian et al. (2007)). Dong et al. (2007) did the interaction
analysis between various PrP fusion proteins and the tubulin in vitro, where the
native tubulin was extracted from rabbit brain tissues (Dong et al. (2007)).
• In 2008, it was said that “ovine prion protein renders rabbit epithelial RK13 cells
permissive to the multiplication of ovine prions, thus providing evidence that
species barriers can be crossed in cultured cells through the expression of a rel-
evant ovine PrPC” (Courageot et al. (2008)). Sakudo et al. (2008) “developed
a mammalian expression system for a truncated soluble form of human prion
protein with the native signal peptide but without a glycosylphosphatidylinositol
(GPI)-anchor site, driven by the peptide chain elongation factor 1alpha promoter
in stably transfected rabbit-kidney epithelial RK13 cells, to investigate the SOD
(superoxide dismutase) activity of mammalian prion protein” and concluded
“GPI-anchorless human prion protein is secreted and glycosylated but lacks su-
peroxide dismutase activity” (Sakudo et al. (2008)). Shin et al. (2008) cloned a
prion protein (PrP) Glu218Lys gene from Korean bovine (Bos taurus coreanae)
and raised the production of rabbit anti-bovine PrP antibody (Shin et al. (2008)).
Lawson et al. (2008) reported “rabbit kidney epithelial cells (RK13) are permis-
sive to infection with prions from a variety of species upon expression of cognate
PrP transgenes” (Lawson et al. (2008)).
• In 2009, Hanoux et al. (2009) reported “when injected into rabbits, (a synthetic
peptide) CDR3L generated anti-SAF61 anti-Id polyclonal antibodies that exclu-
sively recognized SAF61 mAb but were unable to compete with hPrP for anti-
body binding” (Hanoux et al. (2009)). Tang et al. (2009) reported fibrinogen,
one of the most abundant extracellular proteins, has chaperone-like activity: it
maintains thermal-denatured luciferase in a refolding competent state allowing
luciferase to be refolded in cooperation with rabbit reticulocyte lysate, and it also
inhibits fibril formation of yeast prion protein Sup35 (NM) (Tang et al. (2009)).
Differed from the reaction with N-terminal proline/glycine-rich repeats recog-
nizing rabbit polyclonal antibody, seven monoclonal antibodies (mAbs) against
chicken cellular prion protein (ChPrPC) were obtained (Ishiguro et al. (2009)).
Fernandez-Funez et al. (2009) found RaPrP does not induce neurodegeneration
in the brains of transgenic flies (Fernandez-Funez et al. (2009)).
• In 2010, Nisbet et al. (2010) created a mutant mouse PrP model containing
RaPrP specific amino acids at the GPI anchor site and found that the GPI anchor
attachment site (ω site) controls the ability of PrPC →PrPSc and the residues at ω
andω+1 of PrP are important modulators of this pathogenic process (Nisbet et al.
(2010)). Nisbet et al. (2010) recognized that “rabbits are one of a small number
of mammalian species reported to be resistant to prion infection” (Nisbet et al.
(2010)). Wen et al. (2010) using multidimensional heteronuclear NMR tech-
niques reported that the I214V and S173N substitutions result in distinct struc-
tural changes for RaPrPC (Wen et al. (2010a,b)) and concluded that the highly
ordered β2-α2 loop may contribute to the local as well as global stability of the
RaPrP protein (Wen et al. (2010b)). Wen et al. (2010) also recognized “rabbits
are one of the few mammalian species that appear to be resistant to TSEs due to
9
the structural characteristics of RaPrPC itself” (Wen et al. (2010b)). Fernandez-
Funez et al. (2010) showed that “RaPrP does not induce spongiform degenera-
tion and does not convert into scrapie-like conformers” (Fernandez-Funez et al.
(2010)). Bitel et al. (2010) examined “changes in muscle tissue in a classic
model of diabetes and hyperglycemia in rabbits to determine if similar dysregu-
lation of Alzheimer Aβ peptides, the prion protein (PrP), and superoxide dismu-
tase 1 (SOD1), as well as nitric oxide synthases is produced in muscle in diabetic
animals” (Bitel et al. (2010)). Khan et al. (2010) found the propensity to form
β-state (the β-sheet-rich structure) is greatest for hamster PrP, less for mouse
PrP, but least for the PrP of rabbits, horses and dogs under different conditions
and using two-wavelength CD (Circular Dichroism) method they also found a
key hydrophobic staple-like helix-capping motif keeping the stability of RaPrP’s
X-ray crystallographic molecular structure (Khan et al. (2010)).
• In 2011, Zocche et al. (2011) used the methods “rabbit aortic smooth muscle
cells were challenged for 4, 8 and 18 hours, with angiotensin-II, tunicamycin
and 7-ketocholesterol, and rabbit aortic arteries were subjected to injury by bal-
loon catheter”, and got the results “the PrPC mRNA expression in rabbit aor-
tic artery fragments, subjected to balloon catheter injury, showed a pronounced
increase immediately after overdistension” (Zocche et al. (2011)). Mays et al.
(2011) reported “PrPSc was efficiently amplified with lysate of rabbit kidney
epithelial RK13 cells stably transfected with the mouse or Syrian hamster PrP
gene” (Mays et al. (2011)). Julien et al. (2011) reported the different overall
sensitivities toward NMR urea denaturation with stabilities in the order hamster
= mouse < rabbit < bovine protein, and they also investigated the effect of the
S174N mutation in rabbit PrPC (Julien et al. (2011)). Zhou et al. (2011) found
that the crowded physiological agents Ficoll 70 and dextran 70 have effects sig-
nificantly inhibiting fibrillation of RaPrP (Zhou et al. (2011); Ma et al. (2012)).
Fernandez-Funez et al. (2011) also acknowledged that “classic studies showing
the different susceptibility to prion disease in mammals have recently found sup-
port in structural and transgenic studies with PrP from susceptible (mouse, ham-
ster) and resistant (rabbit, horse, dog) animals” (Fernandez-Funez et al. (2011)).
• In 2012, Chianini et al. (2012) generated rabbit PrPSc in vitro subjecting un-
seeded normal rabbit brain homogenate to saPMCA and found the rabbit PrPSc
generated in vitro is infectious and transmissible (Chianini et al. (2012)) and they
declared “rabbits are not resistant to prion infection” (Chianini et al. (2012)).
Kim et al. (2012) reported “elk prion protein (ElkPrPC) has been confirmed to be
capable of rendering rabbit epithelial RK13 cells permissive to temporal infec-
tion by chronic wasting disease (CWD) prions.” (Kim et al. (2012)). Fernndez-
Borges et al. (2012) reported the results of (Chianini et al. (2012)) and pointed
out it is not reasonable to attribute species-specific prion disease resistance based
purely on the absence of natural cases and incomplete in vivo challenges; the
concept of species resistance to prion disease should be re-evaluated using the
new powerful tools available in modern prion laboratories, whether any other
species could be at risk (Fernndez-Borges et al. (2012)).
• In 2013, Vidal et al. (2013) studied the saPMCA and reported that rabbits are an
apparently resistant species to the original classical cattle BSE prion (Vidal et al.
(2013)). Wang et al. (2013) reported rabbits are “insensitivity to prion diseases”
(Wang et al. (2013)). Wang et al. (2013) aimed to investigate “potential mecha-
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nisms contributing to prion resistance/susceptibility by using the rabbit, a species
unsusceptible to prion infection, as a model” (Wang et al. (2013)) and investi-
gated “the expression level and distribution of LRP/LR (laminin receptor pre-
cursor/laminin receptor) in rabbit tissues by real-time polymerase chain reaction
and by immunochemical analysis with a monoclonal anti-67 kDa LR antibody”
(Wang et al. (2013)) and at last their findings confirmed the prion resistance in
rabbits (Wang et al. (2013)). Sweeting et al. (2013) produced X-ray structures of
mutants in the β2-α2 loop and reported that the helix-capping motif in the β2-
α2 loop modulates β-state misfolding in RaPrP, and still acknowledged “rabbit
PrP, a resistant species” (Sweeting et al. (2013)). Friedman-Levi et al. (2013)
reported “pAb RTC and EP1802Y (EP), a rabbit α PrP mAb directed against the
CITQYER ESQAYYQRGS sequence present at the C-terminal part of human
PrP, just before the PrP GPI anchor” (Friedman-Levi et al. (2013)). Timmes et
al. (2013) used R20 as the rabbit polyclonal anti-PrP antibody (Timmes et al.
(2013)).
Throughout the above review on the research advances in RaPrP, we noticed that the
rabbit prion in (Chianini et al. (2012); Fernndez-Borges et al. (2012)) was just pro-
duced through saPMCA in vitro not by challenging rabbits directly in vivo with other
known prion strains, and the saPMCA result of (Chianini et al. (2012); Fernndez-Borges et al.
(2012)) was refused by the test of cattle BSE (Vidal et al. (2013)). All other RaPrP re-
search results generally agree with each other to look rabbits as a resistant species to
prion diseases.
3. Materials and Methods
Many marvelous biological functions in proteins and DNA and their profound dy-
namic mechanisms, such as cooperative effects (Chou (1989)), allosteric transition
(Chou (1987)), DNA internal motion (Zhou (1989)), intercalation of drugs into DNA
(Chou and Mao (1988)), and assembly of microtubules (Chou et al. (1994)), can be re-
vealed by studying their internal motions as summarized in a comprehensive review
(Chou (1988)). Likewise, to really understand the action mechanism of prion protein,
we should consider not only the static structures concerned but also the dynamical in-
formation obtained by simulating their internal motions or dynamic process. To realize
this, the MD simulation is one of the feasible tools.
The MD simulations of this paper are the continuation and extension of the ones
of (Zhang (2010)). Zhang (2010) carried out (i) 15 ns of production phase of MD
simulations and (ii) the heating phase of MD simulations is starting from 100 K with
one set of initial velocity (denoted as seed2) (Zhang (2010)). This paper continued to
finish another 15 ns of production phase of MD simulations for seed2, and carried out
other two sets of initial velocities for heating from 100 K (denoted as seed1 and seed3)
of MD simulations with 30 ns of production phases.
We furthermore extended the MD simulation of (Zhang (2010)). Under the same
simulation conditions, we also did the MD simulations with the three seeds at room
temperature (300 K) for X-ray structures (PDB entries 3O79 (Khan et al. (2010)),
4HMM (Sweeting et al. (2013))) and the NMR structures (PDB entries 2FJ3, 2JOH,
2JOM), in order to further confirm the MD results of NMR structures. For the three
seeds at room temperature and at 350 K, the MD simulations are also done for human
and mouse prion proteins (PDB entries 1QLX (Zahn et al. (2000)), 1AG2 (Riek et al.
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(1996)) respectively), in order to make a comparison with HuPrP and MoPrP to further
confirm the stability of RaPrP.
In order to get the low pH environment, the residues HIS, ASP, GLU were changed
into HIP, ASH, GLH respectively and Cl- ions were added by the XLEaP module of
AMBER package. Thus, the salt bridges of the neutral pH environment were broken in
low pH environment.
4. Results and Discussions
For seed1∼seed3, at 450 K, during the whole 30 ns, radii of gyrations of the wild-
type and the I214V and S173N mutants have been always level off around 15 angstroms
whether in neutral pH environment or in low pH environment.
In neutral pH environment, compared with the I214V and S173N mutants (whose
three α-helices have been unfolded into β-sheets), the wild-type is always at the lowest
level of RMSD (root mean square deviation), RMSF (root mean square fluctuation)
and B-factor values. This show to us the wild-type RaPrP is very stable under neutral
pH environment. However, under low pH environment (both the wild-type and mutants
have been unfolded their structures from α-helices into β-sheets), we cannot see some
large differences among the wild-type, the I214V mutant and the S173N mutant.
4.1. 450 K
The variations of the molecular structures of the wild-type and during the 30 ns
for the three sets of MD simulations can be seen in Fig. 1, where the graphs were
produced in the use of DSSP program (Kabsch and Sander (1983)), H is the α-helix,
I is the pi-helix, G is the 3-helix or 3/10 helix, B is the residue in isolated β-bridge, E
is the extended strand (participates in β-ladder), T is the hydrogen bonded turn, and
S is the bend; H1, H2, and H3 respectively denote the α-helix 1 (α1), α-helix 2 (α2)
and α-helix 3 (α3) of a prion protein (we denote the β-strand before H1 as β1 and
the β-strand beween H1 and H2 as β2). We can see that for the wild-type the three
α-helices have been still kept during the whole 30 ns of each set under the neutral pH
environment, but under low pH environment, the three α-helices of the wild-type are
unfolded as of the I214V and S173N mutants under neutral or low pH environment and
at last should be unfolded into rich β-sheet structures.
Under low pH environment, the salt bridges of the wild-type (Table 1) are bro-
ken thus leads to the unfolding of the stable helical structures of RaPrP. The follow-
ing salt bridges should contribute to the stability of RaPrP: ASP146-ARG147, GLU210-
ARG207, GLU206-LYS203, GLU206-ARG207, ASP146-HIS139, GLU151-ARG150, GLU151-
ARG147, GLU151-ARG155, ASP177-ARG163, GLU145-ARG135, ASP143-HIS139, GLU145-
HIS139, GLU195-ARG155, ASP146-ARG150, ASP177-HIS176, ASP143-ARG147, GLU195-
LYS193, HIS186-ARG155, HIS186-LYS184, ASP166-ARG163, GLU210-HIS176, HIS139-ARG135,
GLU199-LYS193, GLU206-HIS176. Among these salt bridges, compared with the salt
bridges of I214V and S173N mutants, we find that GLU-195-ARG155 and ASP166-
ARG163 are important to contribute to the structural stability of wild-type RaPrP.
Zhang (2011) found that there always exist salt bridges between ASP202-ARG156,
ASP178-ARG164 in human and mouse prion proteins, between ASP201-ARG155,
ASP177-ARG163 in RaPrP (Zhang (2011b)). The author broke salt bridges of of hu-
man, mouse and rabbit prion proteins by doing MD simulations from neutral to low pH
environment; consequently, the secondary structures of human and mouse prion pro-
teins were not changed very much, while the stable helical structure of wild-type RaPrP
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Figure 1: 450 K: Secondary Structure graphs for the NMR wild-type RaPrP (seed1 to seed3 from up to
down) [x-axis: time (0–30 ns), y-axis: residue number (124–228); left column: neutral pH, right column:
low pH].
13
Salt bridges 450 K 300 K 300 K 350 K
Donor-Acceptor (NMR) (NMR) (X-ray) (NMR)
ASP146-ARG147 (100.0, 100.0, 100.0) (100.0, 100.0, 100.0) (100.0, 100.0, 100.0) (100.0, 100.0, 100.0)
GLU210-ARG207 (99.15, 97.58, 98.43) (99.84, 98.01, 47.02) (99.95, 99.98, 99.74) (99.78, 99.81, 99.84)
GLU206-LYS203 (97.67, 92.85, 87.35) (78.03, 98.85, 91.59) (97.67, 99.12, 96.23) (82.74, 82.98, 98.35)
GLU206-ARG207 (84.25, 84.80, 75.50) (86.90, 65.61, 62.79) (81.49, 83.23, 68.71) (88.85, 98.84, 89.27)
ASP146-HIS139 (*, 73.65, *) (93.74, 34.67, 44.44) (56.70, 90.53, 61.20) (92.62, 80.64, 28.38)
GLU151-ARG150 (72.13, 47.10, 84.25) (94.15, 44.07, 29.83) (47.79, 26.72, 40.83) (76.05, 30.84, 50.65)
GLU151-ARG147 (63.13, 36.28, 64.22) (98.55, 23.69, *) (46.27, 42.27, 50.39) (*, 31.43, 23.11)
GLU151-ARG155 (60.78, *, 60.07) (56.19, *, 57.29) (20.70, *, 57.71)
ASP177-ARG163 (47.80, 40.38, 21.92) (23.93, 31.62, 82.38) (70.59, 26.27, 61.89) (19.54, *, 38.69)
GLU145-ARG135 (33.52, *, 47.13)
ASP143-HIS139 (27.95, *, 10.95) (*, *, 22.43)
GLU145-HIS139 (25.00, *, 18.60)
GLU195-ARG155 (21.88, 7.97, *) (13.39, 55.78, 44.30) (*, *, 32.25)
ASP146-ARG150 (21.23, 66.38, 34.25) (92.55, 34.63, 86.09) (15.15, *, 10.20) (91.38, 62.11, 94.13)
ASP177-HIS176 (21.17, 16.55, 10.15) (15.47, 11.66, *) (21.09, 24.35, 19.69) (*, 25.63, *)
ASP143-ARG147 (19.73, 50.30, 28.38) (93.43, 42.51, 79.52) (53.97, 32.05, 38.03) (86.43, 78.38, 73.68)
GLU195-LYS193 (19.68, 21.98, 10.27) (*, *, 25.35) (52.20, 61.13, 20.80) (*, 15.92, 46.75)
HIS186-ARG155 (14.01, 96.35, 12.47) (100.0, 73.69, *) (81.19, 35.80, 78.98) (71.69, 100.0, *)
HIS186-LYS184 (*, 37.95, 12.95)
ASP166-ARG163 (*, *, 54.08)
GLU210-HIS176 (*, *, 33.37) (74.31, *, *)
HIS139-ARG135 (*, *, 32.02)
GLU199-LYS193 (*, *, 11.95)
GLU199-LYS203 (11.73, *, *)
GLU206-HIS176 (*, *, 11.83) (57.10, *, 75.83)
ASP201-ARG155 (6.62, 6.08, *) (3.95, 37.81, *) (*, *, 10.05) (10.07, *, *)
GLU199-LYS184 (46.57, *, *)
HIS139-ARG150 (50.96, *, *)
ASP166-ARG227 (*, 11.07, *)
Table 1: Salt bridges of the RaPrP wild-type under neutral pH environment for the MD simulations with
occupied rates for seed1, seed2, seed3, where * denotes the occupied rate is less than 10%.
collapsed (Zhang (2011b)). This is to say that the human and mouse prion protein
structures are not affected by removing these salt bridges but the structure of RaPrP is
affected very much by these salt bridges. Therefore, compared with human and mouse
prion proteins, the salt bridges such as ASP201-ARG155, ASP177-ARG163 contribute
greatly to the structural stability of RaPrP.
The salt bridge ASP177-ARG163 is just like a taut bow-string keeping the β2-α2
loop linked. This loop has been a focus on the studies of RaPrP molecular struc-
ture (Sweeting et al. (2013, 2009); Wen et al. (2010b); Christen et al. (2013, 2012);
Damberger et al. (2011); Sigurdson et al. (2011, 2010); Prez et al. (2010); Christen et al.
(2009); Sigurdson et al. (2009); Christen et al. (2008); Gossert et al. (2005); Lhrs et al.
(2003); Stanker et al. (2012); Cong et al. (2013); Bett et al. (2012); Meli et al. (2011);
Rossetti et al. (2010); Kirby et al. (2010); Zhang (2011a, 2012)).
Recently, Garrec et al. (2013) reported that the salt linkage of HIS187 and ARG136
of mouse PrP causes “two misfolding routes for the prion protein” (Garrec et al. (2013)).
For RaPrPC, we found that at HIS187 the salt bridge HIS186-ARG155 contributes to
the structural stability (Table 1).
4.2. At 300 K (Room Temperature)
We found at the room temperature 300 K, RaPrP has a clear difference from HuPrP
and MoPrP: under low pH environment, the three α-helices of RaPrP are unfolded for
all the seeds (Fig. 2) but for HuPrP and MoPrP the three α-helices have not unfolded
during the long 30 ns of MD simulations. This implies to us the broken of salt bridges
under low pH environment has not affected the structure of HuPrP and MoPrP very
much, and indicates to us the C-terminal region of RaPrPC has lower thermostability
than that of HuPrPC and MoPrPC.
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Figure 2: 300 K: Secondary Structure graphs for the NMR wild-type RaPrP (seed1 to seed3 from up to
down) [x-axis: time (0–30 ns), y-axis: residue number (124–228); left column: neutral pH, right column:
low pH].
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We also compared with NMR structures with X-ray structures of RaPrP. Generally,
for the wild-type RaPrP, under neutral pH environment at 300 K the three α-helices
have not much unfolded during the whole 30 ns of MD simulations. For the S173N
mutant of RaPrP, the secondary structure of X-ray is very similar as that of NMR
during the 30 ns of MD simulations at 300 K. The RMSD value between 2FJ3.pdb
(NMR, wild-type) and 3O79.pdb (X-ray, wild-type) is 2.791856 angstroms, and be-
tween 2JOH.pdb (NMR, S173N mutant) and 4HMM.pdb (X-ray, S173N mutant) is
2.996173 angstroms. Thus, in this paper we used the NMR structures to replace the
X-ray structures in our MD result analyses.
At 300 K, seeing Table 1 we know that the following salt bridges should contribute
to the structural stability of RaPrP:
• ASP146-ARG147 (in H1),
• GLU210-ARG207 (in H3),
• GLU206-LYS203 (in H3),
• GLU206-ARG207 (in H3),
• ASP146-HIS139 (linking H1 ∼ loop β1-α1),
• GLU151-ARG150 (in H1),
• GLU151-ARG147 (in H1),
• GLU151-ARG155 (in H1),
• ASP177-ARG163 (linking H2 ∼ loop β2-α2),
• ASP143-HIS139 (in loop β1-α1),
• GLU195-ARG155 (linking loop α2-α3 ∼ bend α1-β2),
• ASP146-ARG150 (in H1),
• ASP177-HIS176 (in H2),
• ASP143-ARG147 (in H1),
• GLU195-LYS193 (in loop α2-α3),
• HIS186-ARG155 (linking C-terminals of H2 and H1),
• GLU199-LYS203 (in H3),
• ASP201-ARG155 (linking H3 with the C-terminal of H1).
All these salt bridge stabilizing interactions added up can make an important contribu-
tion to the overall stability of RaPrPC. Same as at 450 K, we have also found that at
300 K during the long 30 ns the salt bridge ASP177-ARG163 is very strong and always
keeps the linking of H2 and the loop β2-α2 (Sweeting et al. (2013, 2009); Wen et al.
(2010b); Christen et al. (2013, 2012); Damberger et al. (2011); Sigurdson et al. (2011,
2010); Prez et al. (2010); Christen et al. (2009); Sigurdson et al. (2009); Christen et al.
(2008); Gossert et al. (2005); Lhrs et al. (2003); Stanker et al. (2012); Cong et al. (2013);
Bett et al. (2012); Meli et al. (2011); Rossetti et al. (2010); Kirby et al. (2010); Zhang
(2011a, 2012)). Observing Fig. 2, we can clearly see that under low pH environment
the lose of the salt bridges in H1 made H1 unfolded completely. In Fig. 2, for seed2 un-
der low pH environment, H2 has not unfolded; this almost agrees with the observation
from Fig. 3 of (Zhang (2011b)).
4.3. At 350 K
Similarly, we found at temperature 350 K, RaPrP has a clear difference from HuPrP
and MoPrP: under low pH environment, the three α-helices of RaPrP are unfolded for
all the seeds (Fig. 3) but for HuPrP and MoPrP the three α-helices have not unfolded
during the long 30 ns of MD simulations.
At 350 K, all the salt bridges listed in Table 1 added up can make an important con-
tribution to the overall stability of RaPrPC. Same as at 450 K, we have also found that at
350 K during the long 30 ns the salt bridge ASP177-ARG163 is very strong and always
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Figure 3: 350 K: Secondary Structure graphs for the NMR wild-type RaPrP (seed1 to seed3 from up to
down) [x-axis: time (0–30 ns), y-axis: residue number (124–228); left column: neutral pH, right column:
low pH].
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keeps the linking of H2 and the loop β2-α2 (Sweeting et al. (2013, 2009); Wen et al.
(2010b); Christen et al. (2013, 2012); Damberger et al. (2011); Sigurdson et al. (2011,
2010); Prez et al. (2010); Christen et al. (2009); Sigurdson et al. (2009); Christen et al.
(2008); Gossert et al. (2005); Lhrs et al. (2003); Stanker et al. (2012); Cong et al. (2013);
Bett et al. (2012); Meli et al. (2011); Rossetti et al. (2010); Kirby et al. (2010); Zhang
(2011a, 2012)). Observing Fig. 3, we can clearly see that under low pH environment
the lose of the salt bridges in H1 made H1 unfolded completely, and H2 is almost
unfolded. In Fig. 3, for seed3 under low pH environment, H3 is unfolded.
4.4. Hydrogen Bonds
A salt bridge is actually a combination of two noncovalent interactions: hydrogen
bonding and electrostatic interactions. From neutral pH to low pH, the electrostatic
interactions were lost, and it also made the lost of some (weak noncovalent) hydrogen
bonding interactions at the same time which made the unfolding of H1∼H3. This
is because an α-helix is mainly maintained by hydrogen bonding interactions (HBs)
and in an ideal α-helix there are 3.6 residues per complete rotating so a rotation of
100o per residue. We found under neutral pH environment there are HBs ASP177-
ARG163, ASP201-ARG155, which have highly occupied during the long 30 ns of MD
simulations for seed1∼seed3 at 450 K, 300 K and 350 K (Fig.s 4∼5).
5. Conclusion
Like the controversy on “prion” theory, there is also a big controversy over “whether
rabbits are resistant to prion infection or not?”. This paper briefly reviewed the re-
search results on RaPrP and rabbit prions. This paper also did MD simulation studies
on RaPrP and its I214V and S173N mutants with some preliminary analyses of the role
of salt bridges that plays in the structural stability of RaPrP. The survey shows to us
that rabbits were not challenged directly in vivo with other known prion strains and the
saPMCA result did not pass the test of the known BSE strain of cattle. Thus, we might
still look rabbits as a prion resistant species (and the concept of species resistance to
prion disease should be re-evaluated using new powerful tools because it is not rea-
sonable to attribute species-specific prion disease resistance just based purely on the
absence of natural cases and incomplete in vivo challenges (Huang et al. (2013))). MD
results indicate that the three α-helices of the wild-type are stable under the neutral pH
environment, and the three α-helices of the mutants (I214V and S173N) are unfolded
into rich β-sheet structures under the same pH environment. In addition, we found an
interesting result that the salt bridges such as ASP201–ARG155, ASP177–ARG163,
HIS186-ARG155 contribute greatly to the structural stability of RaPrP.
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